Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end ...
Robert F. Kennedy Jr., President Trump’s nominee to be health secretary, would have oversight power over the vaccine’s maker, ...
Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.
Robert F. Kennedy Jr., Trump’s pick to be health secretary, is keeping his financial stake in major vaccine litigation ...
Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in its portfolio. "Keytruda has ...
Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...
Zacks.com on MSN6d
Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...
Yahoo Finance senior health reporter Anjalee Khemlani explains the process and the range of other drugs on this new list from pharmaceutical giants Pfizer (PFE), AstraZeneca (AZN), Merck (MRK ...
Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback